ArticleCancer innovation2026

Rationale and Trial Design of DAWNA-FES Trial: Single-Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [

Ru Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.